NASDAQ:ATRC

AtriCure Stock Forecast, Price & News

$76.37
+0.25 (+0.33 %)
(As of 06/23/2021 01:15 PM ET)
Add
Compare
Today's Range
$75.64
$76.43
50-Day Range
$64.91
$77.93
52-Week Range
$34.04
$80.44
Volume2,452 shs
Average Volume382,586 shs
Market Capitalization$3.48 billion
P/E RatioN/A
Dividend YieldN/A
Beta1.07
30 days | 90 days | 365 days | Advanced Chart
Receive ATRC News and Ratings via Email

Sign-up to receive the latest news and ratings for AtriCure and its competitors with MarketBeat's FREE daily newsletter.


AtriCure logo

About AtriCure

AtriCure, Inc. develops, manufactures, and sells devices for the surgical ablation of cardiac tissue and systems to medical centers in the United States, Europe, Asia, and internationally. It offers Isolator Synergy Clamps, a single-use disposable radio frequency products; multifunctional pens and linear ablation devices, such as the MAX Pen device that enables surgeons to evaluate cardiac arrhythmias, perform temporary cardiac pacing, sensing, and stimulation and ablate cardiac tissue with the same device; and the Coolrail device, which enable users to make longer linear lines of ablation. The company also provides cryoICE Cryoablation System that enables the user to make linear ablations of varied lengths; EPi-Sense Guided Coagulation System, a single-use disposable device used to treat symptomatic persistent and long-standing persistent atrial fibrillation patients; AtriClip System, an implantable device coupled to a single-use disposable applier; and LARIAT System, a suture-based solution for soft-tissue closure compatible with a range of anatomical shapes. In addition, it sells Lumitip Dissectors to separate tissues to provide access to key anatomical structures that are targeted for ablation; COBRA Fusion Surgical Ablation System; Fusion Magnetic Retriever System; and various reusable cardiac surgery instruments, which are used during surgical procedures for repair or replacement of certain heart valves. The company markets and sells its products through independent distributors and direct sales personnel. AtriCure, Inc. was incorporated in 2000 and is headquartered in Mason, Ohio.

Headlines

See More Headlines

Industry, Sector and Symbol

Sales & Book Value

Profitability

Debt

Price-To-Earnings

Miscellaneous


MarketRank

Overall MarketRank

1.74 out of 5 stars

Medical Sector

244th out of 2,105 stocks

Surgical & Medical Instruments Industry

22nd out of 174 stocks

Analyst Opinion: 3.5Community Rank: 2.9Dividend Strength: 0.0Insider Behavior: 1.7Valuation: 0.6 5 -4 -3 -2 -1 -
speech bubbles
speech bubbles











AtriCure (NASDAQ:ATRC) Frequently Asked Questions

Is AtriCure a buy right now?

8 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for AtriCure in the last twelve months. There are currently 8 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" AtriCure stock.
View analyst ratings for AtriCure
or view top-rated stocks.

What stocks does MarketBeat like better than AtriCure?

Wall Street analysts have given AtriCure a "Buy" rating, but there may be better buying opportunities in the stock market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new stock ideas, but AtriCure wasn't one of them. MarketBeat thinks these five companies may be even better buys.
View MarketBeat's top stock picks here.

When is AtriCure's next earnings date?

AtriCure is scheduled to release its next quarterly earnings announcement on Tuesday, July 27th 2021.
View our earnings forecast for AtriCure
.

How were AtriCure's earnings last quarter?

AtriCure, Inc. (NASDAQ:ATRC) posted its quarterly earnings data on Monday, April, 26th. The medical device company reported ($0.38) earnings per share (EPS) for the quarter, meeting analysts' consensus estimates of ($0.38). The medical device company earned $59.28 million during the quarter, compared to analysts' expectations of $56.24 million. AtriCure had a negative net margin of 22.89% and a negative trailing twelve-month return on equity of 10.49%.
View AtriCure's earnings history
.

How has AtriCure's stock been impacted by COVID-19 (Coronavirus)?

AtriCure's stock was trading at $35.28 on March 11th, 2020 when COVID-19 (Coronavirus) reached pandemic status according to the World Health Organization. Since then, ATRC shares have increased by 116.5% and is now trading at $76.37.
View which stocks have been most impacted by COVID-19
.

What guidance has AtriCure issued on next quarter's earnings?

AtriCure issued an update on its FY 2021 earnings guidance on Tuesday, May, 4th. The company provided earnings per share guidance of -1.150--1.150 for the period, compared to the Thomson Reuters consensus estimate of $-1.160. The company issued revenue guidance of $252 million-$256 million, compared to the consensus revenue estimate of $250.29 million.

What price target have analysts set for ATRC?

8 Wall Street analysts have issued 1 year target prices for AtriCure's shares. Their forecasts range from $75.00 to $102.00. On average, they expect AtriCure's stock price to reach $86.25 in the next twelve months. This suggests a possible upside of 12.9% from the stock's current price.
View analysts' price targets for AtriCure
or view top-rated stocks among Wall Street analysts.

Who are AtriCure's key executives?

AtriCure's management team includes the following people:
  • Mr. Michael H. Carrel, CEO, Pres & Director (Age 50, Pay $1.1M)
  • Ms. Angela L. Wirick CPA, Chief Financial Officer (Age 43, Pay $402.24k)
  • Mr. Douglas J. Seith, Chief Operating Officer (Age 55, Pay $693.24k)
  • Mr. Salvatore Privitera J.D., Chief Technical Officer (Age 54, Pay $471.15k)
  • Mr. Justin J. Noznesky, Chief Marketing & Strategy Officer (Age 43, Pay $470.38k)
  • Dr. Vinayak Doraiswamy, Chief Scientific Officer
  • Mr. Karl S. Dahlquist, Chief Legal Officer
  • Ms. Tonya Austin, Chief HR Officer
  • Valerie Storch-Willhaus, VP of Corp. Marketing & Communications
  • Mr. Theodore L. Polin, Corp. Sec.

What is Michael Carrel's approval rating as AtriCure's CEO?

25 employees have rated AtriCure CEO Michael Carrel on Glassdoor.com. Michael Carrel has an approval rating of 100% among AtriCure's employees. This puts Michael Carrel in the top 10% of approval ratings compared to other CEOs of publicly-traded companies.

Who are some of AtriCure's key competitors?

What other stocks do shareholders of AtriCure own?

What is AtriCure's stock symbol?

AtriCure trades on the NASDAQ under the ticker symbol "ATRC."

Who are AtriCure's major shareholders?

AtriCure's stock is owned by many different retail and institutional investors. Top institutional shareholders include BlackRock Inc. (8.53%), Fred Alger Management LLC (7.00%), Alliancebernstein L.P. (5.36%), Price T Rowe Associates Inc. MD (4.97%), Champlain Investment Partners LLC (4.77%) and Credit Suisse AG (3.00%). Company insiders that own AtriCure stock include Douglas J Seith, Justin J Noznesky, M Andrew Wade, Mark A Collar, Michael H Carrel, Regina E Groves, Salvatore Privitera, Scott William Drake, Sven Wehrwein and Tonya Austin.
View institutional ownership trends for AtriCure
.

Which major investors are selling AtriCure stock?

ATRC stock was sold by a variety of institutional investors in the last quarter, including Goldman Sachs Group Inc., Sectoral Asset Management Inc, Tamarack Advisers LP, BNP PARIBAS ASSET MANAGEMENT Holding S.A., D. E. Shaw & Co. Inc., TimesSquare Capital Management LLC, Neuberger Berman Group LLC, and Nuveen Asset Management LLC. Company insiders that have sold AtriCure company stock in the last year include Douglas J Seith, Justin J Noznesky, Mark A Collar, Michael H Carrel, Regina E Groves, Salvatore Privitera, Scott William Drake, Sven Wehrwein, and Tonya Austin.
View insider buying and selling activity for AtriCure
or view top insider-selling stocks.

Which major investors are buying AtriCure stock?

ATRC stock was acquired by a variety of institutional investors in the last quarter, including Alliancebernstein L.P., Oak Ridge Investments LLC, Artisan Partners Limited Partnership, Fred Alger Management LLC, Credit Suisse AG, Dimensional Fund Advisors LP, BlackRock Inc., and Clarus Group Inc.. Company insiders that have bought AtriCure stock in the last two years include Regina E Groves, and Scott William Drake.
View insider buying and selling activity for AtriCure
or or view top insider-buying stocks.

How do I buy shares of AtriCure?

Shares of ATRC can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is AtriCure's stock price today?

One share of ATRC stock can currently be purchased for approximately $76.37.

How much money does AtriCure make?

AtriCure has a market capitalization of $3.48 billion and generates $206.53 million in revenue each year. The medical device company earns $-48,150,000.00 in net income (profit) each year or ($1.01) on an earnings per share basis.

How many employees does AtriCure have?

AtriCure employs 750 workers across the globe.

What is AtriCure's official website?

The official website for AtriCure is www.atricure.com.

Where are AtriCure's headquarters?

AtriCure is headquartered at 7555 INNOVATION WAY, MASON OH, 45040.

How can I contact AtriCure?

AtriCure's mailing address is 7555 INNOVATION WAY, MASON OH, 45040. The medical device company can be reached via phone at 513-755-4100.


This page was last updated on 6/23/2021 by MarketBeat.com Staff
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research.